Non-steroidal anti-inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: results from a primary care based inception cohort of patients.
about
Cardiovascular risk in rheumatoid arthritis: assessment, management and next stepsNonsteroidal anti-inflammatory drugs, gastroprotection, and benefit-riskLong-term frequent use of non-steroidal anti-inflammatory drugs might protect patients with ankylosing spondylitis from cardiovascular diseases: a nationwide case-control studyNon-steroidal anti-inflammatory drugs and their benefits and harms: the challenge of interpreting meta-analyses and observational data sets when balanced data are not analyzed and reported.HDL cholesterol efflux capacity in rheumatoid arthritis patients: contributing factors and relationship with subclinical atherosclerosis.Patient benefit-risk in arthritis--a rheumatologist's perspective.Use of non-steroidal anti-inflammatory drugs and risk of incident myocardial infarction and heart failure, and all-cause mortality in the Australian veteran communityExcess risk of hospital admission for cardiovascular disease within the first 7 years from onset of inflammatory polyarthritis.Mechanisms of premature atherosclerosis in rheumatoid arthritis and lupusCardiovascular disease in patients with chronic inflammation: mechanisms underlying premature cardiovascular events in rheumatologic conditions.Effects of Methotrexate on Carotid Intima-media Thickness in Patients with Rheumatoid Arthritis.Management and evaluation of extra-articular manifestations in spondyloarthritisRheumatoid arthritis and cardiovascular disease: an update on treatment issues.Management of cardiovascular risk in patients with rheumatoid arthritis: evidence and expert opinion.Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE.Comparative risks of non-prescription analgesics: a structured topic review and research priorities.The costs and consequences of adequately managed chronic non-cancer pain and chronic neuropathic pain.Spondyloarthritis and inflammatory bowel disease. Comorbidity and treatment implications.Focus on the potential effects of treatments for spondylarthritides on cardiovascular risk.Analgesic safety - myths, mysteries and misconceptions.Prevention of Stroke in Rheumatoid Arthritis.Cardiovascular adverse events by non-steroidal anti-inflammatory drugs: when the benefits outweigh the risks.Impact of non-steroidal anti-inflammatory drugs on cardiovascular risk: Is it the same in osteoarthritis and rheumatoid arthritis?Non-steroidal anti-inflammatory drugs and risk of cardiovascular disease in patients with rheumatoid arthritis: a nationwide cohort study.Cardioprotective Effect of NSAIDs.Nurse management of cardiovascular risk factors in rheumatoid arthritis.Comparative Risk of Cardiovascular Outcomes Between Topical and Oral Nonselective NSAIDs in Taiwanese Patients With Rheumatoid Arthritis.Prevention of stroke in rheumatoid arthritis.Celecoxib exerts protective effects in the vascular endothelium via COX-2-independent activation of AMPK-CREB-Nrf2 signalling.
P2860
Q26744334-097AF0C8-444E-4A82-AF93-564C27E6C64CQ26864640-6D928488-94FD-45E2-968D-CCDE60BC4144Q28547208-A33A16B5-B2B8-440C-A29F-0921840B221EQ30955512-8662C4FE-D66F-45EF-8A87-587AD2278937Q33750044-A4EB290E-C5D1-41AB-8B2B-C28A1D32DD6AQ33803037-B7A71728-428C-4C2B-B022-98DBCA6EB9EFQ33906348-2B105067-20E8-43AB-8A8E-28074FDB71E7Q34125171-E85F96E1-C925-4EA0-AF95-FCA99F3ADB41Q34343906-AD7855F7-5437-422B-8629-B8D4DB8AF3ADQ35121150-5B722182-9410-4198-ABBA-70DD9476C2A4Q36241707-F0C672DF-B4FC-477D-9F60-91100EA260A3Q36439889-67BDF07F-78EC-4FBD-BE1E-E3B1396AB50CQ36812587-70693884-EBB3-437B-98D8-95B012D65879Q37058791-EBBB8A94-02FA-4C47-9D9E-5D023BB4F8BCQ37883018-64A14F5A-39C1-4DF6-80DC-C34A0C833B54Q37947341-6E668F0F-AE77-4F8B-BC35-921832FCE0E3Q38086926-69BB0F5F-CB8E-4669-BEED-E559EA65082CQ38113682-2FC38C28-28ED-449E-BB55-C3A79A1AB56CQ38177340-0D34646F-E2C4-428B-A464-CBAFCCC08B3EQ38439161-5CAA2D0B-63FC-4747-A774-D69FCF4B3AA3Q38612651-B9D8D0FB-D3F8-4532-AE0D-42AEBC0295FDQ38941017-CB4C381E-9779-44B6-B416-7586D56F4BE4Q38962092-59D03BEB-2D53-4B60-8254-FFBFF936B382Q39225848-44593BB1-9806-4486-B76C-AE3E8FC90726Q41188697-DD93F7AB-EC9D-496C-BF63-E9E6DE283446Q44915388-374C88F3-68A7-4091-818E-CE64B7AE7703Q47116867-0BD99C04-729D-4290-9962-2CED510CF1E1Q53502883-039B6F15-4EA8-4557-A11C-02D8FEA23EF0Q54115193-E303DB9B-B019-4283-BD28-26FD0CF89C94
P2860
Non-steroidal anti-inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: results from a primary care based inception cohort of patients.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 April 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Non-steroidal anti-inflammator ...... inception cohort of patients.
@en
Non-steroidal anti-inflammator ...... inception cohort of patients.
@nl
type
label
Non-steroidal anti-inflammator ...... inception cohort of patients.
@en
Non-steroidal anti-inflammator ...... inception cohort of patients.
@nl
prefLabel
Non-steroidal anti-inflammator ...... inception cohort of patients.
@en
Non-steroidal anti-inflammator ...... inception cohort of patients.
@nl
P2093
P2860
P921
P356
P1476
Non-steroidal anti-inflammator ...... d inception cohort of patients
@en
P2093
A J Silman
A M Brookhart
D H Solomon
N J Goodson
P2860
P304
P356
10.1136/ARD.2007.076760
P407
P577
2008-04-13T00:00:00Z